(S1 (S (S (NP (NN Androgen)) (VP (VBZ stimulates) (NP (NP (NN glycolysis)) (PP (IN for) (NP (ADJP (FW de) (FW novo)) (NN lipid) (NN synthesis)))) (PP (IN by) (S (VP (VBG increasing) (NP (NP (DT the) (NNS activities)) (PP (IN of) (NP (NP (NN hexokinase) (CD 2)) (CC and) (NP (NN 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase) (CD 2)))) (PP (IN in) (NP (NN prostate) (NN cancer) (NNS cells))))))))) (. .)))
(S1 (S (S (NP (NP (NN Up-regulation)) (PP (IN of) (NP (NN lipogenesis))) (PP (IN by) (NP (NN androgen)))) (VP (VBZ is) (NP (NP (CD one)) (PP (IN of) (NP (NP (DT the) (ADJP (RBS most) (JJ characteristic)) (JJ metabolic) (NNS features)) (PP (IN of) (NP (NN LNCaP) (NN prostate) (NN cancer) (NNS cells)))))))) (. .)))
(S1 (S (S (NP (DT The) (JJ present) (NN study)) (VP (VBD revealed) (SBAR (IN that) (S (NP (NN androgen)) (VP (VBZ increases) (NP (NP (NN glucose) (NN utilization)) (PP (IN for) (NP (NP (ADJP (FW de) (FW novo)) (NN lipogenesis)) (PP (IN in) (NP (NN LNCaP) (NNS cells)))))) (PP (IN through) (NP (NP (NP (DT the) (NN activation)) (PP (IN of) (NP (NP (NN HK2)) (PRN (-LRB- -LRB-) (NP (NN hexokinase) (CD 2)) (-RRB- -RRB-))))) (CC and) (NP (NP (NN activation)) (PP (IN of) (NP (NP (DT the) (JJ cardiac) (NN isoform)) (PP (IN of) (NP (NP (NN PFKFB2)) (PRN (-LRB- -LRB-) (NP (NN 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase)) (-RRB- -RRB-)))))))))))))) (. .)))
(S1 (S (S (NP (NP (NN Activation)) (PP (IN of) (NP (NP (NN PKA)) (PRN (-LRB- -LRB-) (NP (JJ cAMP-dependent) (NN protein) (NN kinase)) (-RRB- -RRB-)))) (PP (IN by) (NP (NN androgen)))) (VP (VBD increased) (NP (NP (NN phosphorylation)) (PP (IN of) (NP (NP (NN CREB)) (PRN (-LRB- -LSB-) (NP (ADJP (NN CRE) (-LRB- -LRB-) (NP (JJ cAMP-response) (NN element)) (-RRB- -RRB-) (JJ -binding)) (NN protein)) (-RRB- -RSB-)))) (, ,) (SBAR (WHNP (WDT which)) (S (PP (IN in) (NP (NN turn))) (VP (VBD bound) (PP (TO to) (NP (NN CRE))) (PP (IN on) (NP (NP (DT the) (NN promoter)) (PP (IN of) (NP (NP (DT the) (NN HK2) (NN gene)) (VP (VBG resulting) (PP (IN in) (NP (NP (JJ transcriptional) (NN activation)) (PP (IN of) (NP (DT the) (NN HK2) (NN gene)))))))))))))))) (. .)))
(S1 (S (S (NP (NP (NN Up-regulation)) (PP (IN of) (NP (NN PFKFB2) (NN expression)))) (VP (VBD was) (VP (VBN mediated) (PP (IN by) (NP (NP (DT the) (JJ direct) (NN binding)) (PP (IN of) (NP (JJ ligand-activated) (NN androgen) (NN receptor))) (PP (TO to) (NP (DT the) (NN PFKFB2) (NN promoter)))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (VBN activated) (NP (NP (NN PI3K)) (PRN (-LRB- -LRB-) (NP (NN phosphoinositide) (NN 3-kinase)) (-RRB- -RRB-))) (NN /Akt) (NN signalling) (NN pathway)) (PP (IN in) (NP (NN LNCaP) (NNS cells)))) (VP (VBZ contributes) (PP (TO to) (NP (NP (DT the) (NN phosphorylation)) (PP (IN of) (NP (NN PFKFB2))) (PP (IN at) (NP (NP (NNP Ser466)) (CC and) (NP (NNP Ser483)))))) (, ,) (S (VP (VBG resulting) (PP (IN in) (NP (NP (DT the) (JJ constitutive) (NN activation)) (PP (IN of) (NP (NN PFK-2) (-LRB- -LRB-) (NN 6-phosphofructo-2-kinase) (-RRB- -RRB-) (NN activity))))))))) (. .)))
(S1 (S (S (NP (NP (NN Glucose) (NN uptake)) (CC and) (NP (NN lipogenesis))) (VP (VBD were) (ADVP (RB severely)) (VP (VBN blocked) (PP (PP (IN by) (NP (NP (JJ knocking-down)) (PP (IN of) (NP (NP (NN PFKFB2)) (VP (VP (VBG using) (NP (NN siRNA))) (-LRB- -LRB-) (NP (JJ small) (VBG interfering) (NN RNA)) (-RRB- -RRB-)))))) (CC or) (PP (IN by) (NP (NP (NN inhibition)) (PP (IN of) (NP (NN PFK-2) (NN activity))) (PP (IN with) (NP (NN LY294002) (NN treatment))))))))) (. .)))
(S1 (S (S (VP (VBN Taken) (ADVP (RB together)))) (, ,) (S (NP (PRP$ our) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (DT the) (NN induction)) (PP (IN of) (NP (ADJP (FW de) (FW novo)) (NN lipid) (NN synthesis))) (PP (IN by) (NP (NN androgen)))) (VP (VBZ requires) (NP (NP (NP (DT the) (JJ transcriptional) (NN up-regulation)) (PP (IN of) (NP (NP (NN HK2)) (CC and) (NP (NN PFKFB2))))) (, ,) (CC and) (NP (NP (NN phosphorylation)) (PP (IN of) (NP (NP (NN PFKFB2)) (VP (VBN generated) (PP (IN by) (NP (DT the) (NN PI3K/Akt) (NN signalling) (NN pathway) (S (VP (TO to) (VP (NN supply) (NP (NP (DT the) (NN source)) (PP (IN for) (NP (NP (NN lipogenesis)) (PP (IN from) (NP (NN glucose))) (PP (IN in) (NP (NN prostate) (NN cancer) (NNS cells))))))))))))))))))))) (. .)))
